Solid Biosciences Inc. Operating Lease Right-of-Use Assets
Solid Biosciences Inc. (SLDB) had Operating Lease Right-of-Use Assets of $20.67 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Operating Lease, Right-of-Use Asset $20.67M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $21.30M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $21.92M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $22.54M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $20.67M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $21.30M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $21.92M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $22.54M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $23.13M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $23.72M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $24.30M 10-K · filed 2026-03-19 |
| 2024-09-30 | $24.86M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $25.51M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $26.10M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $26.54M 10-K · filed 2025-03-06 |
| 2023-09-30 | $27.19M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $27.84M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $28.31M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $28.95M 10-K · filed 2024-03-13 |
| 2022-09-30 | $28.44M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $28.94M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $722.00K 10-Q · filed 2022-04-27 |
| 2021-12-31 | $1.14M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.22M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $1.58M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $3.20M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $3.58M 10-K · filed 2022-03-14 |
| 2020-09-30 | $3.95M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $4.31M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $4.66M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $4.99M 10-K · filed 2021-03-15 |
| 2019-09-30 | $5.53M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $5.62M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $5.92M 10-Q · filed 2019-05-13 |
| 2019-01-01 | $4.60M 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |